Saint Louis University Journal of Health Law & Policy
Volume 2
Issue 1 Disability, Reproduction & Parenting

Article 6

2008

Embryonic Genetics
Judith F. Daar
Whittier Law School, jdaar@law.whittier.edu

Follow this and additional works at: https://scholarship.law.slu.edu/jhlp
Part of the Health Law and Policy Commons

Recommended Citation
Judith F. Daar, Embryonic Genetics, 2 St. Louis U. J. Health L. & Pol'y (2008).
Available at: https://scholarship.law.slu.edu/jhlp/vol2/iss1/6

This Symposium Article is brought to you for free and open access by Scholarship Commons. It has been accepted
for inclusion in Saint Louis University Journal of Health Law & Policy by an authorized editor of Scholarship
Commons. For more information, please contact Susie Lee.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

EMBRYONIC GENETICS
JUDITH F. DAAR*

I. INTRODUCTION
Advances in reproductive medicine are notorious for yielding previously
unthinkable methods of enhancing human procreation, alongside equally
unanticipated ethical and social dilemmas. The introduction of
preimplantation genetic diagnosis (PGD) produced such dual consequences
and continues to challenge traditional notions of health and medical
decision-making. PGD is a medical technique originally developed in
England in the late 1980s as a method of detecting single-gene disorders in
unimplanted three-day old embryos.1 The basic PGD procedure involves
the creation of embryos via in vitro fertilization (IVF), followed by the
extraction via biopsy of a single cell, known as a blastomere, from the threeday old, eight-celled embryo.2 Because each blastomere is totipotent in the
early embryo—meaning it has “all potential” and can develop into a
separate, wholly intact new embryo—studying this single cell reveals the
genetic make-up of the embryo from which it was taken.3 PGD can detect

* Associate Dean for Academic Affairs, Professor of Law, and Harry S. Zekian Scholar, Whittier
Law School. I am grateful to Elizabeth Pendo for inviting me to participate in the 2008 Saint
Louis University School of Law Health Law Symposium. Heartfelt gratitude is also extended to
Russell Korobkin, Taimie Bryant, and Robert Goldstein from UCLA School of Law for vetting a
condensed version of this piece. Finally, I want to thank David Smolin for including me in the
February 2008 symposium sponsored by the Center for Biotechnology, Law, and Ethics at
Cumberland Law School at Samford University, where I presented an earlier version of this
paper.
1. A.H. Handyside et al., Biopsy of Human Preimplantation Embryos and Sexing by DNA
Amplification, LANCET, Feb. 18, 1989, at 347, 348; KRISTINE BARLOW-STEWART & MONA SALEH,
CENTRE FOR GENETICS EDUCATION, FACT SHEET 18, at 1 (2007), available at
www.genetics.edu.au/pdf/factsheets/fs18.pdf (last visited Feb. 3, 2009).
2. See AUDREY HUANG, GENETICS & PUB. POL’Y CTR., PREIMPLANTATION GENETIC
DIAGNOSIS (2006), available at www.dnapolicy.org/images/issuebriefpdfs/PGD_Issue_
Brief.pdf (last visited Feb. 3, 2009); Handyside et al., supra note 1.
3. According to Dr. Machelle M. Seibel, “Preimplantation genetic diagnosis (PGD) is
very much like an amniocentesis performed after fertilization but before the pregnancy is
implanted. IVF is performed, and the embryo is allowed to divide up to at least four cells and
usually up to eight cells. A small hole is made in the zona pellucida and one or two cells of
81
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whether an embryo is genetically normal, or whether it expresses a genetic
anomaly associated with a disease or disorder.4
Because of its role in assisted conception, PGD joins the sundry medical
techniques under the rubric “assisted reproductive technologies” (ART).
PGD’s initial usage was limited to prospective parents anxious to birth a
child unaffected by a genetic disorder that had plagued the family’s lineage
for generations.5 Inevitably, interest in surveying the genetic make-up of
early embryos grew to encompass clinical scenarios likely not contemplated
by the technique’s originators.6 In addition to screening to discover the
genetic health of the conceptus, today ART physicians can use PGD to
screen embryos so that, if later born alive, the resulting children’s blood,
organs, or tissues can be used to support the health of another person,
often a whole blood sibling.7 An even more recent use of PGD is the
selection of embryos based on parental preferences for offspring whose
sensory or mobility capabilities reflect that of their genetic parent or

the embryo are removed, fixed on a slide and analyzed by molecular biology testing. The
molecular biology tools used to perform PGD are either polymerase chain reaction (PCR),
which is a method that amplifies a single gene defect so that it can be seen on a gel
electrophoresis, or fluorescent in situ hybridization (FISH), which stains a particular piece of
DNA with a fluorescent color that can be seen using a special microscope. The diagnosis is
made within a few days, and the unaffected embryos are then transferred into the mother's
uterus so that pregnancy can occur.” AMY BERLIN COOK ET AL., ADOPTION AND REPRODUCTIVE
TECHNOLOGY LAW IN MASSACHUSETTS §9.7 (Susan L. Crockin ed., 2000); Ashley Bumgarner,
Note, A Right to Choose?: Sex Selection in the International Context, 14 DUKE J. GENDER L. &
POL’Y 1289, 1294 (2007).
4. PGD is used to detect two types of genetic anomalies: (1) inherited chromosomal
abnormalities in which a gene or portion of a gene contains a mutation, causing such
disorders as Tay-Sachs disease, Duchene muscular dystrophy, cystic fibrosis, and Huntington’s
disease, or (2) sporatic (non-inherited) aneuploidy, in which the genome contains either too
few or too many chromosome in one or more of the 23 pairs. See HUANG, supra note 2
(discussing aneuploidy and inherited genetic disorders). Some of the more well-known
disorders associated with aneuploidy include Down syndrome (also known as “Trisomy 21,” or
three chromosomes in 21st pair), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy
13) and Klinefelter syndrome (XXY, having an extra “X” sex chromosome). See NAT’L HUM.
GENOME RESEARCH INST., CHROMOSOME ANALYSIS (2005), available at www.genome.gov/
Pages/Education/Modules/ChromosomeAnalysis.pdf (last visited Feb. 3, 2009) (discussing
chromosomal disorders).
5. See Susannah Baruch et al., Genetic Testing of Embryos: Practices and Perspectives
of U.S. In Vitro Fertilization Clinics, 89 FERTILITY & STERILITY 1053, 1053 (2008).
6. See, e.g., id. at 1055 (though PGD was developed to screen unborn children for
genetic disorders, today PGD can be used to select the sex of an embryo “to satisfy the
preferences of the future parents.”).
7. Id.; Bill Radford, The Designer Baby: Right or Wrong?, BALTIMORE SUN, Jan. 14,
2001, at 1N.
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parents.8 The following true-life stories explain each of three PGD
scenarios.
Vignette 1: Using PGD for the Health of the Embryo. Chicago resident
Chad Kingsbury suffered the loss of his mother, maternal grandfather, and
two maternal uncles from an inherited form of colon cancer.9 As a carrier of
the genetic mutation associated with familial susceptibility to the adult-onset
disease, Chad was terrified that his children would inherit his predisposition
to colon cancer.10 For the Kingsburys, PGD “offered them a way to reload
the genetic dice.”11 The couple joined a growing pool of prospective
parents with heritable cancer-susceptibility genes who turned to ART to
assure the birth of a child free of the family genetic mutation.12 In addition
to colon cancer susceptibility, PGD can now be used to screen for other
genetically-based adult-onset diseases including Huntington’s disease,
Alzheimer disease, and breast cancer.13 While the Kingsburys took months
to make the decision to use PGD, the result was a child free of the colon
cancer gene.14 While talking to reporters about his child’s conception,
Chad Kinsbury gazed at daughter Chloe and remarked, “I couldn’t imagine
them telling me my daughter has cancer . . . when I could have stopped
it.”15
Vignette 2: Using PGD for the Health of Another Person. By 1999, Lisa
and Jack Nash’s five-year old daughter Molly was nearing death from
Fanconi’s anemia, an inherited genetic disorder that leads to bone marrow
failure and early forms of cancer.16 Her only hope for recovery was a
compatible stem cell donor, but exhaustive searches within her family and
her community failed to produce a suitable donor.17 The Nashes consulted
Yuri Verlinsky, director of the Reproductive Genetics Institute in Chicago,

8. Liza Mundy, A World of Their Own, WASH. POST, Mar. 31, 2002 (Magazine), at 22.
9. Amy Harmon, Couples Cull Embryos to Halt Heritage of Cancer, N.Y. TIMES, Sept. 3,
2006, at A1. (reporting that “one in every 200 Americans carry a genetic mutation that makes
them susceptible to breast or colon cancer.”).
10. Id.
11. Id. at A20.
12. Id.
13. A recent survey reveals that twenty-eight percent of ART “clinics have provided PGD to
avoid an adult-onset disease such as Huntington disease, hereditary breast cancer, or
Alzheimer disease.” Baruch et al., supra note 5, at 1055.
14. Harmon, supra note 9, at A20.
15. Id.
16. See Dan Vergano, Custom Baby Saves a Life, USA TODAY, Jan. 8, 2001, at 7D;
Radford, supra note 7; Deborah Josefson, Couple Select Healthy Embryo to Provide Stem
Cells for Sister, 321 BRIT. MED. J., 917, 917 (2000).
17. Radford, supra note 7, at 9N; Liza Acevedo, Stem Cell Siblings, SCIENCENTRAL, Sept.
9, 2004, at www.sciencentral.com/articles/view.php3?article_id=218392351&cat=3_2 (last
visited Feb. 3, 2009).
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who pioneered the technique of testing embryos for genes that make
antigens—structures that determine whether tissues will be compatible with a
transplant recipient.18 Using IVF and PGD, physicians were able to identify
which of the Nashes’ embryos were both free of the Fanconi’s anemia gene
and a tissue match for Molly.19 On August 29, 2000, the family welcomed
Adam, a healthy child whose umbilical cord blood was prepared for transfer
into Molly.20 Within a few months, Molly had regained much of her strength
and thereafter went on to make near full recovery.21
Vignette 3: Using PGD to Satisfy Parental Preferences. Long-time
partners Sharon Duchesneau and Candace McCullough wanted a child that
resembled them in one important way.22 The couple was deaf, and their
idea of the perfect child was one who could move in and appreciate the
deaf culture that was defining for the prospective parents.23 The women
inquired of the local sperm bank, only to learn that deafness is a
disqualifying trait for sperm donors; thus no suitable sperm was available in
the marketplace.24 Determined to maximize the chances their child would
be deaf, they turned to a deaf friend who agreed to serve as a sperm
donor.25 Six years later, the couple were parents to a daughter and a son,
both deaf.26 Though Sharon and Candace’s journey to parenthood did not
involve the use of PGD (which can detect genetic deafness), their story
prompted researchers to ask whether physicians would be willing to provide
the technique to cull embryos for certain genetic anomalies.27 A survey
published in 2006 indicates that at least a few IVF centers have assisted in
selecting for a “disability” such as deafness or dwarfism.28

18. Radford, supra note 7, at 9N; Acevedo, supra note 17; Scott Gottlieb, Scientists
Screen Embryo for Genetic Predisposition to Cancer, 322 BRIT. MED. J. 1505, 1505 (2001).
19. See Gottlieb, supra note 18.
20. See Josefson, supra note 16.
21. Radford, supra note 7; Cable News Network, Health, Genetic Selection Gives Girl a
Brother and a Second Chance, Oct. 3, 2000, at http://archives.cnn.com/2000/HEALTH/10/
03/testube.brother/ (last visited Nov. 21, 2008) (having received a transplant from sibling,
Molly now has an eighty-five percent chance survival rate; Molly will not recover fully and will
continue experiencing other symptoms of the disease throughout her lifetime).
22. See Mundy, supra note 8, at 24; Darshak M. Sanghavi, Wanting Babies Like
Themselves, Some Parents Choose Genetic Defects, N.Y. TIMES, Dec. 5, 2006, at F5.
23. See Mundy, supra note 8, at 25.
24. See id. at 24.
25. See id.
26. See id. at 26.
27. See Sanghavi, supra note 22.
28. Baruch et al., supra note 5, at 1055 (noting that “[t]hree percent of IVF-PGD clinics
report having provided PGD to couples who seek to use PGD to select an embryo for the
presence of a [disease or] disability.”).
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The availability and use of PGD layers a social choice atop a medical
decision. Parents who choose to implant only those embryos that offer
compatible tissue for an ailing child simultaneously make the decision to
discard or defer development of otherwise healthy embryos because they
lack utility for an immediate purpose. Parents whose family trees are dotted
with relatives devastated by certain genetically-based diseases must decide
in the earliest moments of conception whether to eliminate embryos that
bear the mutation, or entrust the health of their offspring to the uncertainty
of future medical advances. Parents with sensory or other deficits who
desire a similarly-abled child may discard genetically healthy embryos in
pursuit of their vision of the perfect child. Each of these scenarios calls into
question traditional notions of health, disability and reproductive choice.
Part II of this article chronicles the use of PGD and other reproductive
technologies from their inception to current practices, observing that each
advance has produced some unintended consequence. The ability to mesh
human gametes in the laboratory, form embryos, freeze embryos for later
use, and cull embryonic cells for their rich genetic story has been essential to
family formation. Yet these advances have simultaneously introduced
conflicts and harms that were unimaginable in a pre-ART world. Part II
briefly surveys a few of the inadvertent consequences wrought by a staple in
the ART arsenal—IVF. Examples include genetic parenthood after divorce,
after death, and even after learning that one’s embryos were mistakenly
transferred to another patient with an overlapping clinic appointment. The
law can and has responded to these scenarios with familiar tools borrowed
from family law, tort law, contract law, and other sources. PGD, as the
newest reproductive technology, can draw upon some of the same
disciplines when mishaps occur, but the unintended consequences of
embryonic genetics are more subtle and arguably more globally
problematic.
Part III of this article surveys the use of PGD as described in Vignette 1—
to assess embryonic health as a means of birthing a child free of known
genetic anomalies.29 At least three conundrums emerge when parents
29. Vignettes 2 and 3, using PGD for the health of another, and for the preferences of the
parents, are not treated in depth herein, though each scenario has generated robust
discussion in the legal literature. For discussion on genetic enhancement and engineering, as
well as issues arising from the use of PGD see, for example, Kirsten Rabe Smolensky, Creating
Children with Disabilities: Parental Tort Liability for Preimplantation Genetic Interventions, 60
HASTINGS L.J. 299 (2008); Dov Fox, Silver Spoons and Golden Genes: Genetic Engineering
and the Egalitarian Ethos, 33 AM. J. LAW & MED. 567 (2007); Michele Goodwin, My Sister’s
Keeper?: Law, Children, and Compelled Donation, 29 W. NEW ENG. L. REV. 357 (2007);
Donna M. Gitter, Am I My Brother’s Keeper? The Use of Preimplantation Genetic Diagnosis to
Create a Donor of Transplantable Stem Cells for an Older Sibling Suffering from a Generic
Disorder, 13 GEO. MASON L. REV. 975 (2006); Lindsey A. Vacco, Comment, Preimplantation
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attempt to orchestrate the implantation of a genetically healthy child. First,
there is what I’ll call “the spectrum problem.” PGD can detect whether the
offspring will be likely or even certain to express symptoms of the identified
condition, but it often cannot determine the severity of such manifestation.30
Moreover, as we increasingly recognize the genetic basis of human health,
we are able to detect propensity for diseases that will not manifest until the
fourth or fifth decade of life. Distinguishing between childhood and adultonset diseases, as well as between severe, mild, and benign conditions, is
both morally and medically difficult in the context of adjusting access to
genetic technologies. This essay offers an assessment tool, in the form of a
multi-factorial questionnaire with assigned point values for each response,
as one response to the spectrum problem. Fixing values, even crudely, to
factors such as severity of symptoms and timing of disease onset, may aid in
understanding the proper uses of PGD to maximize embryo health.
A second conundrum evoked by PGD is its shifting of responsibility for
health from person to parent. Part III describes “the shifting problem,”
noting that PGD may also shift the way we view health in the future. A
parent’s ability to spare a child from a disease for which the parent has a
genetic susceptibility means that parent and child may act very differently in
their health-related decisions. While the parent may make lifestyle choices
to reduce the risk of disease onset, including the use of therapeutics or even
prophylactic surgeries, the child will be medically unburdened, possibly
unprepared to accept anything less than perfect health that could come in
the form of sporadic disease or traumatic injury. Additionally, as control
over health shifts from person to parent, those prospective parents who
access reproductive technologies (and even those who do not) may come
under increasing pressure to use PGD to avoid even mild anomalies. This
pressure to utilize genetic technologies to avoid all genetic anomalies—
herein labeled “the expectation problem”—represents the third conundrum
in the trilogy. Part III discusses the expectation interests that genetic
technologies raise, focusing on the expectations of prospective parents and
the society into which their children are born.

Genetic Diagnosis: From Preventing Genetic Disease to Customizing Children. Can the
Technology Be Regulated Based on the Parents’ Intent?, 49 ST. LOUIS U. L.J. 1181 (2005);
Susan M. Wolf et al., Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor:
Issues, Guidelines & Limits, 31 J. LAW, MED. & ETHICS 327 (2003). The goal of this article is to
examine the motivations, expectations, and consequences that can accompany a decision to
use PGD for the health of the embryo. It is my hope that these foundational observations will
inform future discussions about other PGD uses.
30. Human Genetics Alert, Response to HFEA Consultation on Sixth Edition of the Code
of Practice, at www.hgalert.org/topics/geneticSelection/hga_response.htm (last visited Feb. 3,
2009).
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Advances in reproductive medicine can evoke the myth of Sisyphus
pushing his stone up a mountain only to see it roll back as he nears the
summit.31 In a crude sense, today’s version of the myth pits reproductive
scientists, who toil to advance the technology surrounding assisted
conception, against observers who sometimes push back against advances
that alter the traditional course of reproduction. The introduction and
subsequent refinement of PGD display these push-pull qualities, producing
stunning achievements in reproductive medicine, while instilling enormous
unease over our newfound ability to manipulate the human genome. What
follows are arguments for pushing the nascent science of reprogenic
medicine up the mountain, and counterarguments for letting it roll right
back down. In my view, at the end of the day, unlike Sisyphus, PGD will
make sustainable and essential progress in advancing human health.
II. UNINTENDED CONSEQUENCES IN ART
Breakthroughs in the nascent field of reproductive medicine have yielded
a host of unintended consequences. Since the introduction of IVF in
1978,32 the technique is credited with the birth of over three million children
worldwide.33 Combined with other ARTs such as artificial insemination by
donor, oocyte donation, and surrogate parenting arrangement, IVF gives
prospective parents increasing choice and control over their reproductive
futures. The successful integration of ART into modern society is evident by
the numbers alone: today, three out of every one hundred children in the
U.S. are born as a result of some form of assisted conception.34 Moreover,

31. See ALBERT CAMUS, THE MYTH OF SISYPHUS 5 (Raymond Soulard, Jr. & Kassandra
Soulard eds., 2006) (1942).
32. The world’s first “test tube” baby, Louise Brown, was born outside London on July 25,
1978. See Peter Gwynne, All About That Baby, NEWSWEEK, Aug. 7, 1978, at 66, 67. Louise
was conceived using IVF, a medical technique in which the egg and sperm are introduced
under the glare of a laboratory petri dish, instead of in the dark quiet recesses of a woman’s
fallopian tube. Id. Once the sperm fertilizes the egg, the resulting embryo is nurtured in the
lab for several days and then transferred into a woman’s uterus where it will, hopefully,
implant and develop until birth. Id.
33. See European Society for Human Reproduction and Embryology; Three Million Babies
Have Been Born Using Assisted Reproductive Technologies, WOMEN’S HEALTH LAW WKLY., July
16, 2006, at 77 (referencing a 2006 report by the International Committee for Monitoring
Assisted Reproductive Technologies estimating the use of one million ART cycles a year,
producing approximately 200,000 babies worldwide).
34. According to an annual report published by the Centers for Disease Control and
Prevention (CDC), in 2005 (the most recent year for which figures are available) there were
52,041 children born in the U.S. who were conceived using some form of assisted
reproductive technology (ART), as defined by the CDC to include only those techniques in
which both the egg and the sperm are handled. In 2005, ninety-nine percent of all ART cycles
measured by the CDC used IVF, with fewer than one percent using the related techniques of
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the use of ART, particularly IVF, has increased every year since 1995, the
first year in which such data was collected.35 Though fundamentally
grounded in medicine, today’s reproductive technologies nimbly navigate
from petri dish culture to business culture36 to popular culture.37 Yet despite

gamete intrafallopian transfer (in which eggs and sperm are transferred into the fallopian tube)
and zygote intrafallopian transfer (in which the early embryo is transferred into the fallopian
tube). See CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T. OF HEALTH & HUM. SERVS.,
2005 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY
CLINIC REPORTS 61, 85 (2007), available at www.cdc.gov/ART/ART2005/508PDF/2005ART
508.pdf (last visited Feb. 3, 2009) [hereinafter 2005 ART REPORT]. In addition to IVF births, it
is estimated that 60,000 children are born annually via artificial insemination by donor (AID),
a technique in which only the sperm is handled (and thus births by AID are not included in the
annual CDC report). See Inst. for Sci., Law & Tech. Working Group, ART into Science:
Regulation of Fertility Techniques, 281 SCIENCE 651 (1998). Births via IVF and AID bring the
total number of children born through assisted conception to roughly 110,000; the total birth
rate for 2005 was slightly over four million. See CTRS. FOR DISEASE CONTROL & PREVENTION,
U.S. DEP’T. OF HEALTH & HUM. SERVS., Births: Final Data for 2005, 56 NATIONAL VITAL STATISTICS
REPORTS, Dec. 5, 2007, 1, at 1, available at www.cdc.gov/nchs/data/nvsr/nvsr54/
nvsr54_02.pdf (last visited Feb. 3, 2009) (reporting 4,138,349 live births in the U.S. in 2005,
up by approximately one percent from 2004). Thus, total ART births in the U.S. in 2005
comprised slightly over 2.7% of all live births).
35. See 2005 ART REPORT, supra note 34, at 61 (showing ten-year trends in the number
of ART cycles performed from 1996-2005, as well as the number of live-birth deliveries during
that same period using ART. Both ART cycles and deliveries increased by more than double.
The CDC data on ART trends captures data from 1996 forward, excluding data from 1995
because it did not include all reporting U.S. ART clinics).
36. See Michele Goodwin, Assisted Reproductive Technology and the Double Bind: The
Illusory Choice of Motherhood, 9 J. GENDER RACE & JUST. 1, 5, 46-49 (2005). Professor
Goodwin argues that access to ART creates a “double bind” for women in the workplace,
especially professional women whose superiors place subtle pressure on younger women to
defer childbearing to increase their chances of “fair” opportunities at law firms, businesses, or
university posts. ART is seen as a technological bail out for women who put off childbearing,
thus encouraging continued participation in the workplace. Pregnancy and motherhood
discrimination, Professor Goodwin argues, are soft but real discrimination that create “double
binds” for women who believe they must choose between career and early motherhood. See
generally id.
37. The well-publicized use of IVF and gestational surrogacy by celebrities, as well as
incorporation of ART into movie and television plots has contributed to its role in popular
culture. See, e.g., Celebrities Who Have Used IVF and Surrogacy, Part 2, at http://eggdonation-directory.blogspot.com/2007/10/celebrities-who-have-used-ivf-and.html (last visited
Feb. 3, 2009) (listing model and actress Cindy Margolis, actor Chris Meloni, actress Laurie
Metcalf, and anchorwoman Joan Lunden as patrons of gestational surrogates); BABY MAMA
(Universal Studios 2008); see also Internet Movie Database, Synopsis for Baby Mama, at
www.imdb.com/title/tt0871426/synopsis (last visited Feb. 3, 2009); Press Release, Nat’l
Infertility Ass’n, Internet Icon, Supermodel Cindy Margolis to Serve as National Spokesperson
for Resolve: The National Infertility Association (June 7, 2005), at www.resolve.org/site/
PageServer?pagename=fmed_mcpr20050607 (last visited Feb. 3, 2009). The hit ABC
primetime series Ugly Betty included a plot twist involving the use of IVF and surrogacy in early
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ART’s seemingly seamless adoption as a procreative alternative, its rapidly
advancing technical prowess has spawned numerous unexpected dilemmas.
ART’s unintended consequences are best viewed from the perspective of
its two major purposes—to treat infertility and to promote the health of
offspring. Infertility treatment is based on a model in which gametes are
extracted from the body and melded into embryos, many of which are frozen
for later use.38 The presence of gametes and embryos outside the body,
subject to human manipulation, invites scenarios that are only possible in an
ART world. In one New York fertility clinic, a white patient became pregnant
with twin boys, one white and one black, because a laboratory technician
mixed-up two couples’ embryos on the day of transfer.39 The white couple’s
“successful” use of ART inadvertently wrought tremendous pain and suffering
to the black couple whose embryo was negligently misdirected. After a twoyear legal battle, the black child was ordered returned to his genetic
parents, but the debacle caused irreparable harm to both sets of parents.40
This case and others like it disaggregate the roles of race, genetics, and
gestation in determining parenthood, three factors that had heretofore
vested in a single individual.
The freezing of sperm, eggs, and embryos can also produced
unintended results. When a happily married couple undergoes IVF and
freezes excess embryos for future use, they likely do not intend to later
divorce and squabble bitterly over the disposition of those embryos, but such
cases abound.41 When a couple agrees to freeze embryos, neither party
anticipates that the embryos will be released to the other without mutual
consent, but at least several children have been born after their mothers
forged their (non-consenting) fathers’ name on the authorizing
documentation.42 Equally unexpected are decisions about the fate of
2008. Ugly Betty: A Thousand Words by Friday (ABC television broadcast Jan. 24, 2008);
see also ABC.com, Ugly Betty Episode Recaps, at http://abc.go.com/primetime/uglybetty/
index?pn=index (last visited Feb. 3, 2009).
38. See 2005 ART REPORT, supra note 34, at 3, 4.
39. Perry-Rogers v. Fasano, 715 N.Y.S. 2d 19, 21-22 (2000).
40. Id. at 27; see also IVF Mix-Up Heads for Court, BBC NEWS, July 8, 2002, at
http://news.bbc.co.uk/2/hi/health/2115522.stm (last visited Feb. 3, 2009) (summarizing
several cases across Europe and the U.S. in which laboratory mix-ups involving sperm, eggs,
or embryos have resulted in the birth of offspring).
41. See, e.g., Davis v. Davis, 842 S.W.2d 588, 589 (Tenn. 1992); Kass v. Kass, 91
N.Y.2d 554, 560 (1998); A.Z. v. B.Z., 725 N.E.2d 1051, 1053 (Mass. 2000); J.B. v. M.B.,
783 A.2d 707, 710 (N.J. 2001); In Re Marriage of Witten, 672 N.W.2d 768, 768 (Iowa
2003) (all involving litigation over the disposition of frozen embryos upon divorce of the
intended parents).
42. See, e.g., Sarah-Kate Templeton, Wife’s Embryo Fraud Makes Estranged Husband a
Father, SUNDAY TIMES (London), Mar. 2, 2008, at 7, at www.timesonline.co.uk/tol/news/
uk/article3466762.ece (last visited Feb. 3, 2009).
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gametes and embryos after the death of one or more of the intended
parents. With sperm and embryo banks willing to keep material in frozen
storage for decades,43 the phenomenon of posthumous birth—the birth of
genetic offspring after the death of a genetic parent—will become more
routine.44
A final noteworthy unintended consequence of fertility treatment is its
spillover into the emerging world of embryonic stem cell research. When
researchers at the University of Wisconsin announced in the fall of 1998
they had succeeded in isolating and cultivating stem cells from human
embryos, ART suddenly developed a second identity as a potential for
medical cures.45 The Wisconsin stem cell lines were developed from
embryos donated by couples who had previously undergone IVF for
reproductive purposes.46 Seeing ART through the fresh lens of stem cell
research focused attention on questions that were part of the backdrop of
assisted conception, but had largely escaped the scrutiny that this type of
research unleashed. Questions about the moral wisdom and legal authority
surrounding the intentional destruction of embryos for research purposes, as
well as the consent necessary to utilize gametes and embryos in medical
experiments, moved front and center in the minds of stakeholders and
observers alike.47
Stem cell research brought public attention to the possible medical
benefits of ART apart from treating infertility, thus broadening the impact of
advances in reproductive medicine from personal and procreative to global

43. On November 1, 2007, a child was born to a forty-three-year old Canadian man
who had stored sperm prior to chemotherapy in 1985. The child’s conception using decades
old thawed sperm, however, was not a record. “The longest-known storage period of sperm
resulting in a live birth is 28 years, according to a 2005 report in the American medical
journal Fertility and Sterility.” Lena Sin, Baby Conceived with Sperm Frozen Long Ago, at
www.canada.com/story.html?id=973186 (last visited Feb. 3, 2009).
44. Several U.S. courts have already grappled with the question of whether a
posthumously born child can be considered the heir of their predeceased parent for purposes
of probate law, with most answering in the affirmative. See, e.g., In re Gillett-Netting v.
Barnhart, 371 F.3d 593, 593-94, 599 (9th Cir. 2004) (all finding in favor of heirship for
posthumously born children); Woodward v. Comm’r of Soc. Sec., 760 N.E.2d 257, 272
(Mass. 2002); Estate of Kolacy, 753 A.2d 1257, 1258 (N.J. 2000). But see Khabbaz v.
Comm’r, Soc. Sec. Admin., 930 A.2d 1180, 1182 (N.H. 2007) (finding child was not a
“surviving issue” of father under state law).
45. See James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human
Blastocysts, 282 SCIENCE 1145, 1145, 1147 (1998).
46. Id. at 1145.
47. See generally RUSSELL KOROBKIN & STEPHEN R. MUNZER, STEM CELL CENTURY: LAW &
POLICY FOR A BREAKTHROUGH TECHNOLOGY (2007) (providing a comprehensive discussion of
these and other issues surrounding embryonic stem cell research).
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and life-saving.48 While ART as a medical therapy may have first emerged
in the public eye with embryonic stem cell research, its origins can be traced
back to PGD.49 Private individuals with family histories of genetic disorders
learned decade earlier of reproductive medicine’s ability to address human
health outside the infertility context.50 PGD made its entrance into medical
literature in 1990 as a method of detecting lethal genetic anomalies in early
embryos, but has since expanded to permit reproductive decision-making on
the basis of speculative health and social criteria.51 Today’s prospective
parents who access PGD can decide how much genetic health to require of
their early embryos, a decision with potential consequences far beyond the
birth of any resulting offspring.52
III. THE USE OF PGD TO ASSURE OFFSPRING HEALTH
The array of genetic disorders and characteristics that PGD can detect
grows with each passing year.
Currently, PGD is performed for
approximately one hundred genetic conditions, each carrying a unique
profile in terms of severity of impact on overall health and onset of somatic
symptoms.53 Some of the detected conditions are fatal in the first years of
life, such as Tay-Sachs disease; others pose serious health risks and often
cause death in early adulthood, such as cystic fibrosis and Huntington’s
disease; still others are associated with an increased predisposition to adultonset diseases such as colon and breast cancer.54 The ability to access this
vast array of genetic information, only some of which is reliably predictive of
disease, enables prospective parents to decide what is, and is not, an
acceptable level of health for their future children.
This power to orchestrate offspring health, however, is rife with problems
of imprecision. Just as geneticists are unable to predict the severity of
certain conditions, parents are likewise unable to predict the impact these
health choices will have on their offspring, on themselves, and on society at
large. What follows is an effort to isolate, describe, and analyze the

48. See Sarah Franklin, Embryonic Economies: The Double Reproductive Value of Stem
Cells, 1 BIOSOCIETIES 71, 71, 80 (2006) (discussing the influence of IVF on stem cell
research).
49. See Carl T. Hall, Stem Cell Research May Be Boon to Fertility Clinics, S.F. CHRON.,
Feb. 21, 2005, at A6.
50. See Howard W. Jones, Jr. & Jean Cohen, Chapter 14: Preimplantation Genetic
Diagnosis, 87 FERTILITY & STERILITY (Supplement 1) S47, S47 (2007).
51. Id. at S47, S49.
52. Id.
53. See HUANG, supra note 2.
54. See Baruch et al., supra note 5, at 1054; Press Release, Human Fertilisation &
Embryology Authority, HFEA Licenses PGD for Inherited Colon Cancer (Nov. 1 2004), at
www.hfea.gov.uk/en/1049.html (last visited Feb. 3, 2009).
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variables associated with the use of PGD to detect embryo health. For ease
of reference, I categorize the variables into three areas which I’ll label “the
spectrum problem,” “the shifting problem,” and “the expectation problem.”
A.

The Spectrum Problem

If medicine is an art, then medical genetics may be best described as
abstract expressionism for its break from the traditions of the past in a
manner that can be jarring and incomprehensible. But as any fan of Willem
de Kooning will croon, the vibrancy and energy of his colorful abstract
canvases helped pave the way for a new generation of artists.55 Likewise
medical genetics breaks from the diagnostic practices of the past, offering
predictions and prophylaxis long before any symptoms present. Our current
understanding of genetics provides clarity with respect to certain disease
processes, while remaining frustratingly out of focus for a host of other
genetic anomalies. Questions of when, whether, and how severely a
disease will manifest embody the spectrum problem.
PGD can detect whether a resulting child’s genome will contain a
genetic anomaly associated with a particular disease, but often it cannot
predict how the disease will be expressed during the child’s life.56 For
example, both Down syndrome and cystic fibrosis can be detected through
PGD, but to date there is no clinical measure for the severity of symptoms
associated with the diseases. According to the National Institutes of Health,
“Down syndrome symptoms vary from person to person and can range from
mild to severe.”57 The National Down Syndrome Congress concurs, adding
that “[t]here is wide variation in mental abilities, behavior and physical
development in individuals with Down syndrome. Each individual has
his/her own unique personality, capabilities and talents.”58 The Cystic
Fibrosis Foundation likewise advises that the course of cystic fibrosis varies

55. For information about Willem de Kooning, see Guggenheim Collection, Artist - de
Kooning - Biography, at www.guggenheimcollection.org/site/artist_bio_36.html (last visited
Feb. 3, 2009).
56. PGD remains susceptible to human and laboratory error, and misdiagnosis is a
clinical reality. See, e.g., Y. Verlinsky et al., Accuracy and Outcomes of 3631 Preimplantation
Genetic Diagnosis (PGD) Cycles Performed in One Center, 84 FERTILITY & STERILITY
(Supplement 1) S98 (2005) (reporting misdiagnosis in PGD, resulting in an accuracy rate of
99.5%).
57. U.S. NAT’L LIBRARY OF MEDICINE & NAT’L INST. OF HEALTH, MEDICAL ENCYCLOPEDIA:
DOWN SYNDROME, at www.nlm.nih.gov/medlineplus/ency/article/000997.htm (last visited
Feb. 3, 2009).
58. Nat’l Down Syndrome Congress (NDSC), Facts About Down Syndrome, at
www.ndsccenter.org/resources/package3.php (last visited Feb. 3, 2009).
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from person to person.59 Symptoms such as lung infections and coughing
can be mild or severe.60 On a hopeful note, the Foundation reports that the
predicted median age of survival of a cystic fibrosis patient rose to 36.5
years in 2008, up from 32 years in 2000.61
Genetic diseases can also vary in terms of the phase in life in which they
manifest. While diseases such as Tay-Sachs62 and Fanconi’s anemia63
manifest at or near birth, other disorders such as Alzheimer disease64 and
Huntington’s disease65 may not become clinically noticeable until
adulthood. Still other PGD-detectible genetic anomalies are associated with
disease susceptibility, as opposed to disease certainty.66 For example,
families in which many individuals have been diagnosed with breast or
colon cancer may share a genetic mutation that increases an affected
individual’s chances of developing the disease in adulthood.67 Women who

59. See Cystic Fibrosis Found., Frequently Asked Questions, at www.cff.org/AboutCF/
Faqs/ (last visited Feb. 3, 2009).
60. See id.
61. See id.
62. According to the National Institute of Neurologic Disorders and Stroke, “[e]ven with
the best of care, children with Tay-Sachs disease usually die by age 4, from recurring
infection.” Nat’l. Inst. of Neurological Disorders and Stroke, Nat’l Inst. of Health, NINDS TaySachs Disease Information Page, at www.ninds.nih.gov/disorders/taysachs/taysachs.htm (last
visited Feb. 3, 2009).
63. Fanconi’s amenia is a form of inherited anemia that leads to bone marrow failure.
See Fanconi Anemia Research Fund, Diagnosis, at www.fanconi.org/aboutfa/Diagnosis.htm
(last visited Feb. 3, 2009). Fanconi’s anemia usually reveals itself before children are twelve
years old, with symptoms such as skeletal anomalies, kidney problems, and blood
abnormalities. Id.
64. While most forms of Alzheimer’s disease are thought to be sporadic, a small
percentage are considered familial. Inherited Alzheimer disease is associated with earlier
onset of symptoms, sometimes as soon as age thirty-five, compared to the average age of sixty
for other forms of the disease. See Found. for Genomics & Population Health, IVF Embryos to
Undergo Screening for Early-Onset Alzheimer’s Disease (Oct. 1, 2007), at www.phg
foundation.org/news/3778/ (last visited Feb. 3, 2009); ALZHEIMER’S DISEASE EDUC. & REFERRAL
CTR., NAT’L INST. ON AGING, NAT’L INST. OF HEALTH, FACT SHEET: ALZHEIMER’S DISEASE, at 1,
available at www.nia.nih.gov/NR/rdonlyres/7DCA00DB-1362-4755-9E87-96DF669EAE20/
11209/84206ADEARFactsheetAlzDiseaseFINAL08DEC23.pdf (last visited Feb. 3, 2009).
65. Huntington’s disease is a “hereditary, degenerative brain disorder for which there is,
at present, no effective treatment or cure.” Huntington’s Disease Soc’y of America, What is
Huntington’s Disease (HD), at www.hdsa.org/about/our-mission/what-is-hd.html (last visited
Feb. 3, 2009). According to the Huntington’s Disease Society of America, “HD typically
begins in mid-life, between the ages of 30 and 50, though onset may occur as early as the
age of 2. Children who develop the juvenile form of the disease rarely live to adulthood.” Id.
66. See HUANG, supra note 2.
67. NAT’L CANCER INST., NAT’L INST. OF HEALTH, FACT SHEET: GENETIC TESTING FOR BRCA1
AND BRCA2: IT’S YOUR CHOICE at 1-2 (2002), available at www.cancer.gov/images/
Documents/abcb7812-a132-4e78-a532-f002c92fa9b9/fs3_62.pdf (last visited Feb. 3,
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possess the gene mutation associated with the inherited form of breast
cancer are three to seven times more likely to develop the disease than
women without the genetic mutation.68 Individuals with certain forms of
inherited colon cancer are highly likely, but not absolutely certain, to
develop the disease before the age of fifty.69 Calculating the likelihood of
disease expression—referred to as “penetrance”70—is further complicated
by the availability of prophylactic surgery. In some cases, the onset of
cancer may be avoided by removing the susceptible organs and tissues from
the body.
These spectra of symptoms, time of onset, penetrance, and availability
of treatment or prophylaxis create challenges for promulgating a monolithic
view on the use of PGD to screen for embryo health. That said, absolutist
views have been expressed. PGD is prohibited in several countries71 and is
opposed by the Catholic Church, which teaches that all embryos “ought
always to be born from an act of love and should already be treated as a
person.”72 The basis for PGD, the creation of extracorporeal embryos using
IVF, is a per se violation of the Catholic requirement that embryonic life
result only from heterosexual intercourse.73 To add clarity to this rejection of
PGD, in March of 2008 the Church added certain “destructive bioethics
practices” to its list of mortal sins, including “experiments that manipulate
DNA or harm embryos”.74 While PGD itself was not named as a specific

2009) [hereinafter NAT’L CANCER INST., BRCA1 AND BRCA2 FACT SHEET]; see American Cancer
Soc’y, Heredity and Cancer, at www.cancer.org/docroot/CRI/content/CRI_2_6x_Heredity_
and_Cancer.asp (last visited Feb. 3, 2009) [hereinafter ACS, Heredity and Cancer].
68. NAT’L CANCER INST., BRCA1 AND BRCA2 FACT SHEET, supra note 67, at 1.
69. See ACS, Heredity and Cancer, supra note 67.
70. The penetrance of a genetic anomaly is defined as “the probability that the genotype
will be reflected in the phenotype and will have consequences for health.” Guido de Wert &
Joep P.M. Geraedts, Preimplantation Genetic Diagnosis for Hereditary Disorders that Do Not
Show a Simple Mendelian Pattern: An Ethical Exploration, in CONTEMPORARY ETHICAL DILEMMAS
IN ASSISTED REPRODUCTION 85, 88 (Françoise Shenfield & Claude Sureau eds., 2006).
71. PGD is prohibited by law in Germany, Italy, and Switzerland. Jones & Cohen, supra
note 50.
72. See Address of His Holiness Benedict XVI to the Participants in the Plenary Assembly of
the Pontifical Council for the Family (May 13, 2006), at www.vatican.va/holy_father/
benedict_xvi/speeches/2006/may/documents/hf_ben-xvi_spe_20060513_pc-family_en.html
(last visited Feb. 3, 2009).
73. See, e.g., Address of His Holiness Pius XII to the Second World Congress in Naples
on Human Reproduction and Sterility (May 19, 1956).
74. Steven Ertelt, Catholic Church Says Abortion, Cloning, Embryo Destruction Are Sinful
Practices, LIFENEWS.COM, (Mar. 10, 2008), at www.lifenews.com/int652.html (last visited Feb.
3, 2009).
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sin, its requisite extraction of embryonic DNA could be interpreted as both
manipulative and harmful to embryos.75
In December of 2008 the Church updated its absolutist position on ART
in the “Instruction on Dignitas Personae on Certain Bioethical Questions.”76
This Instruction, issued in response to the development of “new biomedical
technologies,” specifically addressed PGD and declared that the procedure
“constitutes an act of abortion” because it “is directed toward the qualitative
The Church
selection and consequent destruction of embryos.”77
categorized PGD as an
expression of a eugenic mentality that ‘accepts selective abortion in order to
prevent the birth of children affected by various types of anomalies. Such
an attitude is shameful and utterly reprehensible, since it presumes to
measure the value of a human life only within the parameters of “normality”
and physical well-being, thus opening the way to legitimizing infanticide and
euthanasia as well.’78

Absolutist views in favor of PGD for medical screening of embryos have
also appeared.79 At least two subsets of absolutism co-exist in the ethics
literature on the subject of prenatal genetic technologies.80 One subset
advocates that prospective parents have a positive moral duty to use genetic
technologies to enhance the well-being of their offspring, enabling them to
live longer, run faster, think clearer, and so on.81 A second subset frames
the positive duty in terms of preventing foreseeable medical harm to children
by selecting against embryos that bear a known genetic anomaly.82 The
former subset is perhaps best represented by John Harris, a Professor of
Bioethics at the University of Manchester, who argues in his recent book that

75. Id. The issue of physical harm to the long-term health of the embryo has been
studied, and recent reports indicate that PGD does not negatively affect embryo health and
development. See Jeanine Cieslak-Janzen et al., Multiple Micromanipulations for
Preimplantation Genetic Diagnosis Do Not Affect Embryo Development to the Blastocyst Stage,
85 FERTILITY & STERILITY 1826, 1828 (2006).
76. The Holy See, Congregation for the Doctrine of the Faith, Instruction, Dignitas
Personae on Certain Bioethical Questions, at www.vatican.va/roman_curia/congregations/
cfaith/documents/rc_con_cfaith_doc_20081208_dignitas-personae_en.html (last visited Feb.
3, 2009).
77. Id.
78. Id. (citing John Paul II, Encyclical Letter Evangelium Vitae (Mar. 25, 1995), at
www.vatican.va/holy_father/john_paul_ii/encyclicals/documents/hf_jp-ii_enc_25031995_
evangelium-vitae_en.htm) (last visited Feb. 3, 2009).
79. See John Harris, Getting Better All the Time, 122 NEW HUMANIST, Nov/Dec 2007, at
20, 20; see also ALLEN BUCHANAN ET AL., FROM CHANCE TO CHOICE: GENETICS AND JUSTICE 1819 passim (2000).
80. See Harris, supra note 79, at 20-21; see BUCHANAN ET AL., supra note 79.
81. See Harris, supra note 79, at 20-21.
82. See BUCHANAN ET AL, supra note 79, at 156.
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“it is not only feasible to use genetic technology to make people more
healthy, intelligent and longer-lived, it’s our moral duty to do so.”83 Harris
considers that “[t]he denial of beneficial enhancements to others, whether
they are our children or strangers, would be a breach of two of the most
powerful moral principles, the duty to do good and the duty not to harm;
whereas the consequences of that denial would leave someone more
vulnerable to harm and less able to lead a healthy, fulfilling life.”84 These
outcomes, Harris argues, support a positive moral duty to utilize genetic
enhancements, including PGD.85
The latter absolutist approach, which favors a positive duty to prevent
offspring harm (but not necessarily a duty to enhance an otherwise healthy
individual), is adopted by philosophers Allen Buchanan, Dan Brock,
Norman Daniels, and Daniel Wikler in their book, From Chance to Choice:
Genetics and Justice.86 These esteemed moral and political philosophers
debate the uses of genetic screening technologies and enhancements,
concluding “that both justice and our obligations to prevent harm make
genetic interventions to prevent disabilities not only permissible but also
obligatory.”87 Absolutist views that PGD must be used by prospective
parents—either to maximally enhance their offspring’s physical and mental
attributes, or to prevent known genetically-based disabilities—dismiss the
spectrum problem as irrelevant. As long as the child could experience some
deficit as a result of a genetic anomaly, the moral balance weighs in favor
of PGD use and embryo selection. Absolutist views that PGD must never be
used are likewise refractory to the spectrum problem. Since respect for
embryos is the central feature of this position, no degree of disability would
justify screening or discarding early human life.88

83. Harris, supra note 79, at 20. Professor Harris’ book, ENHANCING EVOLUTION: THE
ETHICAL CASE FOR MAKING PEOPLE BETTER “champions the possibility of influencing the very
course of evolution to give us increased mental and physical powers—from reasoning,
concentration, and memory to strength, stamina, and reaction speed. Indeed, he supports
enhancing ourselves in almost any way we desire. And it's not only morally defensible to
enhance ourselves, Harris says. In some cases, it's morally obligatory.” Princeton Univ. Press,
Harris, J.: Enhancing Evolution: The Ethical Case for Making Better People, at
http://press.princeton.edu/titles/8480.html (last visited Feb. 3, 2009).
84. Harris, supra note 79, at 21.
85. Id.
86. BUCHANAN ET AL., supra note 79, 156-257 (discussing implications of “Genetic
Perfection” and the duty to prevent harm).
87. Id. at 302.
88. While absolutist views have been expressed on the use of PGD, numerous middle
ground positions pepper the debate over the use of PGD. See generally NICHOLAS AGAR,
LIBERAL EUGENICS: IN DEFENCE OF HUMAN ENHANCEMENT (2004) (explaining that some
commentators take the view that parents should have autonomy to utilize available
technologies to determine what is in the best interest of their future children—but they should
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Adopting an absolutist view toward the use of PGD for medical
screening has the benefit of nullifying the spectrum problem. If one is
always in favor of or always against PGD, then the clinical realities of
particular genetic disorders will hold no sway over the absolutist’s position.
But if one is open to weighing the merits of PGD on a case-by-case basis, or
along some multi-factorial algorithm, then it would be useful to marshal the
various points along the spectra identified with genetic disease. Such an
algorithm could be used to identify the instances when the use of PGD is
most acceptable, such as to avoid transmission of fatal childhood disorder,
or when its use is more questionable, such as when the genetic anomaly has
low penetrance and produces mild, treatable symptoms in the later decades
of life.
Table 1 provides a tool for the numeric assessment of the merits of PGD
for embryo health screening. The Table sets out four factors that determine
the clinical significance of a given genetic anomaly—severity of disease,
onset of disease, penetrance of disease, and availability of treatment or
prophylaxis—together with three points along the spectrum for each factor.
Using a point allocation system, basic parameters for the non-absolutist
position on PGD can be set out. The strongest cases mark the end points.
For example, lethal Tay-Sachs disease would fall in the “should be
permitted” category, while a (as of now theoretical) mutation that poses a 5
percent likelihood of causing color blindness in late adulthood would
represent the “should be discouraged” category. The majority of cases
would fall somewhere in between the end points, in the neutral “can be
permitted” arena. Even in these cases, it may be possible to more
definitively resolve the question of whether PGD offers greater benefit than

not be compelled to do so. Coined “liberal eugenics,” this discipline respects the voluntary
choices of parents to use genetic techniques that will benefit the child in some way). Authors
Guido de Wert and Joep P.M. Geraedts assert that two philosopher scholars—Carson Strong
and Bonnie Steinbock—have espoused support for open access to PGD for prospective
parents striving to assure maximal health for their offspring. Carson Strong urges adoption of
a medical model in which physicians are “non-directive” toward parental requests for PGD,
meaning they offer unconditional support for this reasonable request for service. See de Wert
& Geraedts, supra note 70, at 87-88 (citing CARSON STRONG, ETHICS IN REPRODUCTIVE AND
PERINATAL MEDICINE: A NEW FRAMEWORK 180 (1997)). Steinbock adopts a reproductive
freedom framework, urging that a woman’s right to control her reproductive life includes the
right to access information that she deems relevant to any procreative decision. While doctors
can discuss concerns about the use of PGD in certain situations, ultimately the decision rests
with the patient. Id. at 87 (citing BONNIE STEINBOCK, PREIMPLANTATION GENETIC DIAGNOSIS
AND EMBRYO SELECTION, A COMPANION TO GENETICS 147-57 in A COMPANION TO GENETHICS
(C. Burley & J. Harris eds., 2002)).
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harm.89 A disease that is fatal, or highly debilitating may rank as PGDworthy even if its penetrance is low or it is an adult-onset disorder.
Casting the spectrum problem as a mathematical equation will do little
to solve the ethical conundrums that PGD poses for non-absolutists, but
organizing the data in a uniform manner can create a template for debate.
While the factors included may not be exhaustive, and the spectrum points
can invite wild speculation about unknowable clinical phenomena, a
numeric approach does provide a means of assessing the relative merits of
individual cases. In an era in which PGD tends to be accessed only by
those with the means to pay its approximately $15,000 price tag,90
questions about whether it should be made available are suppressed by
prevailing market forces in which supply capably meets demands. Should
PGD become more widely available through expanded health insurance
coverage, or even government mandates to provide, a rubric for comparing
essential and nonessential uses of PGD will be invaluable.

89. Admittedly, the terms “benefit” and “harm” are ill-defined in this context. Benefit
could be measured by parental happiness wrought by the ability to control reproductive
choice, or by offspring genetic health. Harm may refer to the risk of damage to or loss of
embryos attributable to the PGD process, or to the morbidity associated with IVF in general.
Moreover, balancing benefits and harms pays homage to a utilitarian calculus, in which
actions are judged ethically acceptable when they produce greater benefits than harms
overall.
90. See Barbara Collura, Nat’l Infertility Ass’n, The Costs of Infertility Treatment, at
www.resolve.org/site/PageServer?pagename=lrn_mta_cost (last visited Feb. 3, 2009).
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Table 1. Assessing the Merits of PGD for Medical Screening of Embryos
Factor 1

Factor 2

Factor 3

Factor 4

Severity of
Disease

Onset of
Disease

Likelihood of
Disease/
Penetrance

Availability of
Treatment or
Prophylaxis

a) The disease
is fatal

a) At birth or
early childhood

a) 100% likely
to appear

b) The disease
is non-fatal but
debilitating

b) In early
adulthood

b) Greater than
50% likely to
appear

c) The disease
is mild or
benign

c) In later
adulthood

c) Less than
50% likely to
appear

a) No
treatment or
prophylaxis
b) Some
treatment for
symptom
control
c) Effective
prophylaxis
available

a = 1, b = 2, c = 3.
Assessing Outcomes by Total Points:
4-6
PGD avoid serious harm and should be permitted
7-9
PGD avoids some harm and can be permitted
10-12 PGD poses more risk than benefit and should be discouraged
B.

The Shifting Problem

A parent’s ability to select for or against certain genetic traits in offspring
challenges the way we have historically viewed health in our society.
Shifting control and responsibility for health status from person to parent
could fundamentally change the way future generations view health risks,
altering their behavior toward themselves and others. What follows is a
discussion of the current landscape of health perspectives and its possible
shift in light of emerging genetic technologies.
1. The Person-Public Dichotomy
Our current world view of health tends to vest responsibility for its
maintenance in two actors: person and public.91 From the person
91. See BUCHANAN ET AL., supra note 79, at 11-12 (discussing the two perspectives for
viewing genetic intervention, the “public health model” and the “personal choice model,”
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perspective, an adult individual enjoys the benefits of maintaining, or suffers
the consequences of neglecting, bodily and mental functions that generally
comprise human health.92 A child’s health is likewise subject to a personaffecting model, with parents or guardians imbued with decision-making
authority over offspring and minor charges.93 While environmental, familial,
social, and a host of other factors impact on a person’s health, the personaffecting model dominates contemporary American constructs of health care
decision-making. So essential is the right of the person to control his or her
health and health care that the principle of patient autonomy sits at the
nadir of contemporary bioethics.94 Autonomous decision-making about
individual health is of such moment in our culture that it currently occupies
the highest echelon of constitutional protection—a right protected against
government interference under the liberty interest of the Due Process Clause
of the Fourteenth Amendment to the U.S. Constitution.95 Individual rights
and responsibilities largely drive health decision-making in the U.S.96
While the person may be supreme, the public health model also
occupies a significant role in directing health in our society. Aided by early
recognition of the need for public health measures in modern society,97
Buchanan writes that the public health model “stresses the production of benefits and the
avoidance of harms for groups[,]” while the personal choice model is based upon on
“individual autonomy.”).
92. See id. at 12.
93. See id. at 13.
94. See generally TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL
ETHICS 99-148 (6th ed. 2008) (1979) (discussing the connection between patient autonomy
and health care decision-making).
95. Cruzan v. Dir., Mo. Dep’t of Health, 497 U.S. 261, 278 (1990) (writing for the
majority, Justice Rehnquist acknowledges, “[t]he principle that a competent person has a
constitutionally protected liberty interest in refusing unwanted medical treatment may be
inferred from our prior decisions.”). The question of whether the right to refuse medical
treatment is a fundamental right is unanswered by the Cruzan majority, though commentators
have posited that because the Court did not use strict scrutiny or expressly say that there was a
fundamental right, no such right arose in the case. E.g., Erwin Chemerinsky, In Defense of
Roe and Professor Tribe, 42 TULSA L. REV. 833, 833 (2007). In the Cruzan dissent, Justice
Brennan, joined by Justices Marshall and Blackmun, said that there is a “fundamental right to
be free of unwanted artificial nutrition and hydration[.]” Cruzan, 497 U.S. at 302. As to a
protected right to consent to medical care, the Court cited to an oft-quoted early twentieth
century New York Court of Appeals decision, in which Justice Cardozo observed, “‘[e]very
human being of adult years and sound mind has a right to determine what shall be done with
his own body[.]’” Id. at 269 (quoting Schloendorff v. Soc’y of N.Y. Hosp., 105 N.E. 92, 93
(1914).
96. See Candace Cummins Gauthier, The Virtue of Moral Responsibility in Healthcare
Decisionmaking, 11 CAMBRIDGE Q. OF HEALTHCARE ETHICS 273, 273-75 (2002).
97. See Jacobson v. Massachusetts, 197 U.S. 11 (1905). In upholding a compulsory
vaccination law as a valid exercise of the state’s police power, the Jacobson Court
acknowledged the right of an individual to assert supremacy over the government, but also
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those currently responsible for protecting the public’s health play an
essential role in charting the course for human health. In a sense, public
health principles act as a filter through which individual decisions about
health pass, permitting a broader view of the impact that person-affecting
conduct has on society at large.98 Focusing on population rather than
person, the public health perspective aims to maximize health for the many,
even if it means sacrificing the rights of a few.99
In an era of reproductive genetics in general, and PGD in particular,
applying the person-public dichotomy yields two distinct views of the value
of preimplantation embryo selection. As discussed supra, Philosophers Allen
Buchanan, Dan Brock, Norman Daniels, and Daniel Wikler describe the
dual perspectives from which embryonic genetic intervention can be viewed
as the “public health model” and the “personal choice model.”100 The
public health model relies on “simple and unqualified consequentialist
reasoning” and “looks only to the aggregate balance of good over bad.”101
If PGD, or any genetic intervention, produces an overall benefit for society
(for example, by the birthing of fewer babies with genetic diseases), then the
technique would be assessed as ethically sound.
The utilitarian calculus embedded in the public health model is laudable
for its ease of use, but is often subject to criticism for its failure to recognize
the rights, needs, and harms to individuals. Viewing genetic technologies
from a utilitarian perspective is particularly nettlesome given the devastation
wrought by the early 20th century American eugenics movement.102
“Eugenicists believed that most social problems were caused by hereditary
faults of those afflicted by the problem, and they sought to eventually
eliminate these problems from society through selective breeding.”103 Using
a combination of law and social pressure, American eugenicists convinced
many that society’s greater good would be served by sacrificing the
stated, “it is equally true that in every well-ordered society charged with the duty of conserving
the safety of its members the rights of the individual in respect of his liberty may at times,
under the pressure of great dangers, be subjected to such restraint, to be enforced by
reasonable regulations, as the safety of the general public may demand.” Id. at 29.
98. See id. at 38-39 (holding a state’s interest in protecting its citizens may at times
override individual rights).
99. See BUCHANAN ET AL., supra note 79, at 11.
100. Id.
101. Id.
102. See, e.g., DANIEL J. KEVLES, IN THE NAME OF EUGENICS: GENETICS AND THE USES OF
HUMAN HEREDITY 46-48 (1985); PAUL A. LOMBARDO, THREE GENERATIONS, NO IMBECILES:
EUGENICS, THE SUPREME COURT AND BUCK V. BELL 104, 116 (2008); Alexandra Minna Stern,
Sterilized in the Name of Public Health, 95 AM. J. PUB. HEALTH 1128, 1131-32 (2005).
103. Lisa Powell, Note, Eugenics and Equality: Does the Constitution Allow Policies
Designed to Discourage Reproduction Among Disfavored Groups?, 20 YALE L. & POL’Y REV.
481, 483 (2002).
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reproductive rights of a few.104 The eugenics legacy continues to linger as a
cautionary note to the application of a public health model to advances in
reprogenic medicine.105
The personal service model of genetic technologies, according to
Buchanan and his colleagues, protects private choice as an exercise of
individual autonomy.106 Parents would be free to use PGD, or to decline to
use PGD, as a matter of personal choice irrespective of the consequences to
others.107 The philosophers critique the personal service model for its
elevation of autonomy over all other values, and thereby its potential to
subordinate the autonomy of offspring to that of their parents.108 Despite
these criticisms, the use of PGD in the U.S. today most closely resembles the
personal service model: its availability is based upon a parent’s ability to
pay and a provider’s willingness to supply.109
2. From Person to Parent
The longstanding person-public perspectives on health are well-suited to
a construct in which medical decisions affect the well-being of an existing
individual, but they display signs of obsolescence when health choices are
made on behalf of future generations. The use of PGD allows parents to
wrest control over the health status of their offspring from nature itself.
Moreover, by taking this prenatal control over offspring health, parents can
now make health-related decisions that would heretofore have been made
by the individual—the person whose health is at issue. Thus, PGD shifts
responsibility for basic health status from person to parent, adding a third
lens through which to view the choices and behaviors surrounding health.
Shifting responsibility for health-related decision-making from person to
parent can alter the actions of both person and parent.
In the health paradigm in which an individual’s actions can affect the
well-being of that person’s mind or body, the individual is incentivized to act

104. See id. at 483-484 (quoting HARRY H. LAUGHLIN, EUGENICAL STERILIZATION IN THE
UNITED STATES, A REPORT OF THE PSYCHOPATHIC LABORATORY OF THE MUNICIPAL COURT OF
CHICAGO 446-47 (1922)). “Between 1900 and 1963, at least 60,000 Americans were
sterilized pursuant to eugenic sterilization laws” passed in more than thirty states. Id. “In
response to a lawsuit in 1974 the federal government adopted regulations banning
sterilization without consent in hospitals that receive federal funds, but reports of violations
surface periodically.” Id. at 484.
105. See, e.g., Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our
Eugenics Past–Present, and Future?, 36 CONN. L. REV. 125, 131-132 (2003).
106. BUCHANAN ET AL., supra note 79, at 12-13.
107. See id.
108. Id. at 13.
109. See generally Baruch et al., supra note 5, at 1055-56 (surveying PGD providers’
willingness to perform the technique for medical and social reasons).
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in a way that maximizes health. A person’s understanding of their own
health vulnerabilities are gleaned through various channels providing both
specific and general health information. A person can learn directly about
his or her own health from bouts of ill health, visits with health care
providers, or results of medical testing. In addition, public education plays a
role in individual health by the dissemination of information about risks and
benefits to health via certain activities, foods, and therapeutics. An
individual armed with specific and general health information can adjust
behaviors to promote good health.
For example, a woman with a family history of breast cancer can
undergo a genetic test to see if she possesses of any of the genetic
mutations associated with inherited forms of breast cancer.110 If so, she can
take several steps to reduce and possibly avoid onset of the disease. She
can modify her lifestyle to include a healthier diet and more exercise, both
shown to reduce the risk of disease onset in women with the genetic marker
for breast cancer.111 She can consider taking a drug regimen which studies
show can reduce the chances of developing the disease in some cases.112
And she can opt for prophylactic surgery in which susceptible breast tissue is
removed, thus substantially reducing her chances of developing breast
cancer.113 A woman who knows she is highly susceptible to breast cancer
may be super vigilant about her health in general, taking far fewer health
risks than someone with no such predisposition.
It is understandable that a woman whose life is affected by her genetic
predisposition to breast cancer would want to spare her children such
trauma. Today such a woman could use PGD to select both male and
female embryos that do not bear the known genetic mutation.114 How

110. NAT’L CANCER INST., NAT’L INST. OF HEALTH, U.S. DEP’T OF HEALTH & HUM. SERV., PUB
NO. 05-4252, GENETIC TESTING FOR BREAST AND OVARIAN CANCER RISK: IT’S YOUR CHOICE 2-3
(2005), available at www.cancer.gov/cancertopics/Genetic-Testing-for-Breast-and-OvarianCancer-Risk/pdf (last visited Feb. 3, 2009).
111. See A. Nkondjock et al., Diet, Lifestyle and BRCA-Related Breast Cancer Risk Among
French Canadians, 98 BREAST CANCER RES. & TREATMENT 285, 292 (2006).
112. See Mary-Claire King et al., Tamoxifen and Breast Cancer Incidence Among Women
with Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel
Project (NSABP-P1) Breast Cancer Prevention Trial, 286 JAMA 2251, 2255 (2001) (suggesting
that prophylactic tamoxifen treatment may be effective for women with BRCA2 mutations, but
not for women with BRCA1 mutations. The study tested the efficacy of tamoxifen in reducing
occurrences of breast cancer among cancer-free women with BRCA1 and BRCA2 mutations.).
113. See id.
114. Males who possess the genetic mutations BRCA1 or BRCA2 are at increased risk of
developing breast cancer. Yu Chuan Tai et al., Breast Cancer Risk Among Male BRCA1 and
BRCA2 Mutation Carriers, 99 J. NAT’L CANCER INST. 1811, 1813 (2007); see also Science
Daily, Breast Cancer Risk Elevated in Male BRCA Mutation Carriers, at www.sciencedaily.com/
releases/2007/11/071127171305.htm (last visited Feb. 3, 2009).
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might such a decision impact on the child’s life? At least two possible
behavioral scenarios emerge.
If the child is told about the orchestrated origins of their conception, he
or she might be grateful to the parent for eliminating that particular cancer
risk from their bloodline. But a sense of invincibility could follow. The child,
or later the adult, may feel little incentive to adhere to a healthy lifestyle,
believing that the parent has absorbed all responsibility for the child’s
health. Just as a person with a genetic predisposition can overemphasize
health in their lifestyle, a person purposefully conceived to be free of the
predisposition may be lackadaisical toward their health in general, perhaps
increasing the risk of sporadic illness or traumatic injury. Moreover, a
person who ignores or downplays health maintenance could be woefully
unprepared to cope with injury or illness, compared to a person who does
not take good health for granted.
Alternatively, a person born into a family whose adult members have
suffered the devastating effects of inherited breast cancer may feel both
relief and appreciation for their genetic good fortune. They may have an
enhanced sense of the importance of good health, taking measures to
protect themselves against known health diminishers. At least in the first
generation of PGD use, children born without the genetic mutation will
belong to families in which one or several members are affected by the
cancer susceptibility gene. Watching a loved one suffer can be a powerful
incentive to guard one’s own good health.
I find the latter scenario far more likely and far more consistent with our
past experiences with breakthroughs in disease prevention. PGD may have
certain unique qualities, but it is not the first medical advance to offer
parents an opportunity to protect their children against disease. The
introduction of childhood vaccines allows, and in some cases mandates,115
parents to eliminate the possible onset of harmful diseases including
smallpox,116 polio,117 measles,118 and whooping cough.119 Professor Ronald

115. See Steve P. Calandrillo, Vanishing Vaccinations: Why Are So Many Americans
Opting Out of Vaccinating Their Children?, 37 U. MICH. J. L. REFORM 353, 358, 381-82 &
n.199 (2004) (stating that fifty states have enacted compulsory childhood vaccination laws to
stop the spread of preventable diseases. “The laws require proof of certain immunizations
prior to a child's entry into daycare or school, and provide for exclusion of children not in
conformity.” Nearly all states provide religious exemptions, and about a dozen now have
philosophical opt-outs).
116. Smallpox, “[a]lso known as variola, [is] a highly contagious and frequently fatal viral
disease characterized by a biphasic fever and a distinctive skin rash that left pock marks in its
wake. . . . The disease is caused by the variola virus. The incubation period is about 12 days
(range: 7 to 17 days) following exposure. Initial symptoms include high fever, fatigue, and
head and back aches. A characteristic rash, most prominent on the face, arms, and legs,
follows in 2-3 days. . . . The majority of patients with smallpox recover, but death occurs in
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Green makes an interesting point about the use of vaccines in his recent
book assessing the ethics of PGD.120 In comparing vaccines (disease
prevention) to PGD (genetic enhancement), Green observes, “[w]hen we are
inoculated, the DNA in our white blood cells undergoes irreversible genetic
changes, initiating the synthesis of antibodies to many viruses and bacteria.

up to 30% of cases. Smallpox is spread from one person to another by infected saliva
droplets that expose a susceptible person having face-to-face contact with the ill person.”
MedicineNet.com, Definition of Smallpox, at www.medterms.com/script/main/art.asp?article
key=6328 (last visited Feb. 3, 2009).
117. Polio, short for poliomyelitis, “is a viral disease that can affect nerves and lead to
paralysis. . . . The virus spreads by direct person-to-person contact, by contact with infected
mucus or phlegm from the nose or mouth, or by contact with infected feces. The virus enters
through the mouth and nose, multiplies in the throat and intestinal tract, and then is absorbed
and spread through the blood and lymph system. . . . Between 1840 and the 1950s, polio
was a worldwide epidemic. Since the development of polio vaccines, the incidence of the
disease has been greatly reduced. Polio has been wiped out in a number of countries. There
have been very few cases of polio in the Western hemisphere since the late 1970s. Children
in the United States are now routinely vaccinated against the disease.” U.S. Nat’l Lib. of
Med., MedlinePlus, Poliomyelitis, at www.nlm.nih.gov/medlineplus/ency/article/001402.htm
(last visited Feb. 3, 2009).
118. Measles is caused by a highly contagious virus. “The infection is spread by contact
with droplets from the nose, mouth, or throat of an infected person. For example, sneezing
and coughing can put contaminated droplets into the air. . . . Persons with the measles
typically have a fever, cough, redness and irritation of the eyes (conjunctivitis), and a rash that
spreads. Those who have had an active measles infection or who have been vaccinated
against the measles have immunity to the disease. Before widespread immunization, measles
was so common during childhood that most people became sick with the disease by age 20.
While the number of measles cases dropped over the last several decades to virtually none in
the U.S. and Canada, rates have started to rise again recently.” U.S. Nat’l Lib. of Med.,
MedlinePlus, Measles, at www.nlm.nih.gov/medlineplus/ency/article/001569.htm (last visited
Feb. 3, 2009).
119. Whooping cough, also known as pertussis, “is a highly contagious bacterial disease
that causes uncontrollable, violent coughing. The coughing can make it hard to breathe. A
deep ‘whooping’ sound is often heard when the patient tries to take a breath. . . . When an
infected person sneezes or coughs, tiny droplets containing the bacteria move through the air,
and the disease is easily spread from person to person. . . . Whooping cough can affect
people of any age. Before vaccines were widely available, the disease was most common in
infants and young children. Now that most children are immunized before entering school,
the higher percentage of cases is seen among adolescents and adults.” U.S. Nat’l Lib. of
Med., MedlinePlus, Pertussis, at www.nlm.nih.gov/medlineplus/ency/article/001561.htm (last
visited Feb. 3, 2009).
120. Ronald Green is the Eunice & Julian Cohen Professor for the Study of Ethics and
Human Values and director of the Ethics Institute at Dartmouth College. Dartmouth College,
Ethics Institute, Ronald M. Green, at www.dartmouth.edu/~ethics/about/ronaldgreen.html
(last visited Feb. 3, 2009); RONALD M. GREEN, BABIES BY DESIGN: THE ETHICS OF GENETIC
CHOICE (2007) [hereinafter BABIES BY DESIGN].
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Vaccinations make us superhumans, but no one ridicules enhancements of
this sort.”121
Vaccines, viewed as genetic enhancements or disease prevention, have
not affected the way the inoculated view health in general. Knowing that
one cannot be infected with smallpox or polio does not translate into
recklessness or fearlessness about other health matters. Likewise, PGD,
viewed either as a form of genetic enhancement or disease prevention,
would not affect the way the resulting offspring view their general health.
Knowing that one is protected against a particular disease (inherited forms
of breast or colon cancer, for example) does not change one’s perceived
vulnerability, or lack thereof, toward the myriad other diseases that plague
the human race. While a PGD-selected adult may be less vigilant about
certain diseases, protection against one or several genetic disorders is a
proverbial drop in the bucket when it comes to the array of health maladies
that lurk in any lifetime.
PGD does shift some medical decision-making from person to parent,
but the shift is subtle in the context of the resulting child’s (and later adult’s)
overall health status. Whether disease prevention occurs prenatally or
postnatally is of little moment in the lifetime of the individual spared from
diseases that sickened prior generations. Allowing parents to make choices
that avoid harm to their children seems consistent with the traditional role
that parents have played in protecting and defending the health of their
children. Since disease prevention measures are best practiced sooner than
later in the human life cycle, better we honor the shift of medical decisionmaking from person to parent when deleterious genetic anomalies can be
avoided. Parental stewardship may require nothing less, a debatable point I
refer to as “the expectation problem,” to which I now turn.
C. The Expectation Problem
Since its introduction nearly two decades ago, PGD has received its
share of criticism from the academic ethics community whose concerns
range from the intentional destruction of human embryos to the creation of
a genetic overclass bred to dominate those less-genetically well endowed.122
121. GREEN, BABIES BY DESIGN, supra note 120, at 60.
122. Professor Janet Dolgin provides a succinct summary of the main objections to PGD in
her article titled Method, Mediations, and the Moral Dimensions of Preimplantation Genetic
Diagnosis. She cites the five main moral objections to PGD as: (1) the technique involves
embryo destruction, an impermissible act to those who adhere to the belief that personhood
begins at conception; (2) it commodifies children by reducing their value to the sum of their
distinct traits, rather than their personhood as a whole; (3) it is a form of eugenics because it
allows the selection of embryos (and later persons) with favored traits and the destruction of
embryos with disfavored traits; (4) its high cost impacts principles of distributive justice,
because it is available only to wealthier parents, leaving less wealthy individuals more likely to
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In the context of selection (and thereby deselection) of embryos to maximize
the health of the resulting child, one critique dominates—the concern that a
parent’s choice to use PGD to assure offspring health will convert into
parental duty to do so.123 As the technique is perfected and becomes more
widely available, social pressure will mount to form an expectation that a
child’s well-being is served only by prenatal manipulation of the offspring’s
health status. This “expectation problem” is described by the President’s
Council on Bioethics in their 2004 report, Reproduction and Responsibility,
which warns that “[a]s the aggregate effect of parental choices reshapes
society’s understanding of ‘normal’ or ‘acceptable’ phenotypes, parents
might feel social pressure to undergo PGD, as many pregnant women are
now pressured to undergo amniocentesis.”124
The expectation problem is comprised of two dependent components—
the expectation to use PGD and the expectation to then discard embryos
with genetic anomalies. I label these components as dependent because
the clinical reality is that parents who seek out PGD to detect the health of
their embryos do so in order to implant only those that do not bear an
unhealthy genome.125 What concerns many about the expectation problem
is the lack of boundaries surrounding acceptable uses of the screening
technology. As discussed in Part III(A), the spectrum of genetic disease
penetrance and severity is wide, admitting the possibility that an embryo with
a low likelihood of developing a highly manageable disease could fall prey
birth children with genetic anomalies; and (5) it is an affront to the disabilities community for
its expression of rejection of physical or mental difference in society. See Janet L. Dolgin,
Methods, Mediations, and the Moral Dimensions of Preimplantation Genetic Diagnosis, 35
CUMB. L. REV. 519, 522-26 (2005). Critiques of PGD for its potential to create a genetic
overclass worry “[w]hat the emergence of a genetic overclass will do to the idea of universal
human dignity. . . . [T]o the extent that [young people] become ‘children of choice’ who have
been genetically selected by their parents for certain characteristics, they may come to believe
increasingly that their success is a matter not just of luck but of good choices and planning on
the part of their parents, and hence something deserved. They will look, think, act, and
perhaps even feel differently from those who were not similarly chosen, and may come in time
to think of themselves as different kinds of creatures. They may, in short, feel themselves to be
aristocrats, and unlike aristocrats of old, their claim to better birth will be rooted in nature and
not convention.” FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE: CONSEQUENCES OF THE
BIOTECHNOLOGY REVOLUTION 157 (2002).
123. THE PRESIDENT’S COUNCIL ON BIOETHICS, REPROD. AND RESP.: THE REG. OF NEW
BIOTECHNOLOGIES 96 (2004) (noting that parents might feel socially pressured to undergo
PGD. In addition to social pressure, parents might feel compelled to use PGD for financial
reasons, to avoid having a child with debilitating and costly genetic disorder).
124. Id.
125. The use of PGD for so-called intentional diminishment, described in Vignette 3: Using
PGD to Satisfy Parental Preferences, supra notes 22-28 and accompanying text, could be
viewed as an exception to the general use of the technique to assure the good health and
function of the resulting offspring.
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to the expectation of discard once PGD is performed. While the desire to
avoid birthing a child with a lethal anomaly such as Tay-Sachs disease
might strike all but the most ardent embryo defenders as morally
acceptable, there is growing concern that parents will be pressured to
discard embryos with mild or even benign deviations from the norm.126
The critique that the mere presence of prenatal screening technologies
pressures parents into rejecting “imperfect” offspring is not unique to PGD.
In her book, The Dream of the Perfect Child, Joan Rothschild argues that all
forms of prenatal diagnosis, from ultrasound to amniocentesis to chorionic
villus sampling to PGD,127 create what she terms a “discourse of the perfect
child.”128 This discourse demands that parents reject, via abortion or
embryo discard, anything less than a perfectly healthy child.129 Professor
126. See Jason Christopher Roberts, Customizing Conception: A Survey of Preimplantation
Genetic Diagnosis and the Resulting Social, Ethical, and Legal Dilemmas, 2002 DUKE L. &
TECH. REV., 0012 § IV. Roberts suggests that when multiple embryos are screened there is
“inherent pressure to select only the most desirable traits.” Id. While it is currently not possible
to screen for physical and behavioral traits, there is risk that parents will select only the most
desirable traits, leaving others to “drift randomly among the families of the underclass.” Id.
(quoting LEE SILVER, REMAKING EDEN: CLONING AND BEYOND IN A BRAVE NEW WORLD 225
(1997)).
127. JOAN ROTHSCHILD, THE DREAM OF THE PERFECT CHILD 76-88 (2005).
The
armamentarium of prenatal tests began to build in the late 1950s and early 1960s with the
introduction of ultrasound into obstetric practice. Cynthia M. Powell, The Current State of
Prenatal Genetic Testing in the United States, in PRENATAL TESTING AND DISABILITY RIGHTS 46
(Erik Parens & Adreinne Asch eds., 2000). In the 1970s, physicians began to routinely offer
their pregnant patients maternal serum screening—via a simple blood test—to measure
biochemical markers associated with several conditions in the fetus, including neural tube
impairments such as spina bifida and anencephaly, and Down syndrome. Id. at 45-46.
Today’s pregnant woman can also undergo amniocentesis and chorionic villus sampling
(CVS) to detect fetal chromosomal abnormalities. Id. at 44-48.
According to the Centers for Disease Control and Prevention (CDC), “in 2003, 67
percent of women who had live births [in the U.S.] received ultrasound,” a steady increase
from 47.6% in 1989. CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T. OF HEALTH &
HUMAN SERVS., PUB. NO. (PHS) 2005-1120, Births: Final Data for 2003, NATIONAL VITAL
STATISTICS REPS., 1, 13 (2005). The rate of amniocentesis for 2003 was 1.7%, a decline from
the 3.2% reported in 1989, due in large measure to the increased use of noninvasive
screening tests such as ultrasound and measurement of maternal serum markers. Id. at 14.
The use of maternal serum markers to assess fetal health, commonly referred to as a “triple
screen,” looks for three types of biochemical markers in a pregnant woman’s blood during the
second trimester of pregnancy. Powell, The Current State of Prenatal Genetic Testing in the
United States, supra, at 45-46. Elevated and low levels of certain markers can be associated
with certain neural tube and genetic defects, and often prompt women to follow up an
abnormal finding with ultrasound or amniocentesis. Id.
128. ROTHSCHILD, supra note 127, at 3.
129. See id. at 3-4, 105 (stating that the discourse of the imperfect child arises in clinical
setting, where the parents have to decide whether to keep the pregnancy or terminate it, if the
prenatal diagnosis unveils an imperfect child).
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Rothschild laments the increasingly routine use of prenatal testing, which
fuels the expectation on the part of medical personnel and society at large
that the purpose of testing is to eliminate those with anomalies from the
population.130 “The discourse that emerges in reproductive medicine
characterizes the birth of a child with ‘defects’ as a tragedy, to be avoided
by every means that science and technology can muster.”131
The discourse of the perfect child is particularly troubling to the disability
rights community, who view the discard of “imperfect” embryos as
discrimination against existing persons with disabilities. As explained by
Professors Adrienne Asch and Erik Parens, when a child has a disability, “a
single trait stands in for the whole, the trait obliterates the whole[]” with “no
need to find out about the rest.”132 In the context of disabilities and prenatal
testing, detection of a genetic disability often leads to selective abortion
because the parents view the fetus only in terms of the disability, paying no
regard to the many other qualities of the potential child.133 The parent sees
the prospective child only as the disability, and this single trait enables the
parents to justify their action.134 The abortion is ridding society of the
disability—not of a child who, despite or possibly because of the disability,
could lead a productive and happy life.135
This sequence of events—prenatal diagnosis followed by embryo discard
or selective abortion—sends a message “that disability itself, not societal
discrimination against people with disabilities, is the problem to be
solved.”136 Biologic elimination trumps social accommodation when the
collective decision of prospective parents is to avoid the birth of a child with

130. See id. at 6. Professor Rothschild writes that the promise of a “perfect baby” comes in
the form of technology which is misunderstood “as a guarantor of perfection.” Id. She argues
that while technology allows medical practitioners to cure diseases in adults, children and
fetuses, it also serves “to discover and weed out the imperfect.” Id.
131. Id. at 105.
132. Eric Parens & Adrienne Asch, The Disability Rights Critique of Prenatal Genetic
Testing: Reflections and Recommendations, in PRENATAL TESTING AND DISABILITY RIGHTS 13 (Erik
Parens & Adreinne Asch eds., 2000).
133. See id. at 14.
134. See id. at 13-14. Asch and Parens argue that persons with disabilities are
discriminated against because of a single trait that they bear. Id. Prenatal testing is a form of
discrimination because a single trait revealed during prenatal testing can be enough to
warrant an abortion. Id. at 14. Parents may choose to abort an otherwise wanted fetus
because they see an undesirable trait, not a child as a whole. Id.
135. See id. at 12-17 (Professors Parens & Asch argue that selective abortion discriminates
against disability. With prenatal diagnosis we are trying to screen out and prevent the birth of
children with what we perceive to be undesirable characteristics. Thus, we allow a single trait
to “stand in for the whole” and “obliterate the whole.”).
136. Id. at 13.
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disabilities.137 Why is disability itself a problem, query Asch and Parens?138
The disability rights critique argues that disability is seen as a problem not to
the disabled person (whose main problem is the attitudes of others toward
disability), but rather as a diminishment to the parental experience.139
Having a disabled child, prospective parents worry, will rob them of their
anticipated rearing experience.140 Thus, refusing to gestate or aborting a
disabled child is a way of preserving and upholding parental notions about
the role that reproduction will play in their lives.141 Viewed from the
disability rights perspective, the societal expectation problem described at
the outset is merely a reflection of individual expectations surrounding
reproduction.
Understandably, the disability rights community views the expectation
problem as gravely troubling, posing a “fear of elimination” as parents
select against more and milder anomalies.142 But others defend the
expected use of PGD as a valid, even required, exercise of parental
responsibility. Philosopher Janet Malek stakes out what she calls “the Strong
Claim” on the use of PGD.143 “There are some situations,” she posits, “in
which potential parents are morally required to use reproductive genetic
technologies to reduce the likelihood that their future child will have a
disabling condition.”144 Dr. Malek argues that acting in accordance with
the Strong Claim maximizes the future child’s opportunities and well-being,

137. See generally Parens & Asch, supra note 132, at 12-29.
138. Id. at 13-15, 17-90. In addition to noting that a single trait stands in for the whole
when parents decide whether to have a child with a disability, Parens & Asch present their
“parental attitude argument,” contending that disability becomes an issue when prospective
parents allow it. Id. “If prospective parents imagine that disability precludes everything else
that could be wonderful about a child, they are likely acting on misinformation and
stereotypes.” Id. at 17. If parents understand that a disability is only one of a “fetus’s
characteristics” than they can enjoy being a parent to a child with a disability without “turning
the child into someone she is not.” Id. at 17-18.
139. Id. at 13.
140. Id.
141. See id. Professors Parens and Asch lament this parental view as “unfortunate, often
misinformed” because they overestimate the negative aspects and underestimate the value
and satisfaction of parenting a disabled child. Id.
142. See Suzanne Holland, Selecting Against Difference: Assisted Reproduction, Disability
and Regulation, 30 FLA. ST. U. L. REV., 401, 407-08 (2003) (noting the fear of many disabled
people and some homosexuals that society would wish to eliminate them through prenatal
genetic testing).
143. Janet Malek, Assistant Professor, Dep’t of Med. Human., Brody Sch. of Med., E.
Carolina Univ., Presented at the Saint Louis University School of Law 20th Annual Health Law
Symposium: Disability and the Duties of Potential Parents (Apr. 4, 2008) (PowerPoint
presentation on file with author).
144. Id.
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a special responsibility that parents are ethically obligated to undertake.145
Because parents of existing children are obligated to reduce the likelihood
that they will become disabled, for example by obtaining care for treatable
She
diseases, the obligation to future children is no weaker.146
acknowledges the disability rights critique, but finds that the sources,
incidence, and views of disability are too diverse to be significantly impacted
by the use of PGD.147 On balance, she concludes that the ethical demand
for parental partiality toward their children tip the scales in favor of the
Strong Claim in cases of disabling conditions.148
Both the disability rights critique and the Strong Claim offer commentary
on the expectation problem engendered by the use of PGD to assure
embryo health. The disability community finds the expectation problematic
because it is based on and is calibrated to increase discrimination against
persons with disabilities. From this perspective, PGD is used to eliminate a
would-be person, resulting in negative attitudes and ill-treatment of existing
persons with disabilities.
Defenders of the Strong Claim view the
expectation to use PGD as a moral requisite to good parenting because it
avoids harm to a particular person—the offspring to whom parents owe a
duty of care. Seen from this perspective, PGD eliminates disease, thus
fulfilling the duty of existing persons—the prospective parents.
Is it possible to reconcile these two seemingly opposite views of the
expected use of PGD to assure embryo health? A place to begin may be
with the language, and corresponding perceptions, adopted by each side.
Instead of viewing PGD as a tool for elimination (person/disease), it should
be seen as a means of preventing harm. If both foes and advocates can
agree that harm prevention is a good worth pursuing, then a dialogue can
begin about which harms are worth preventing, and in whom the harms
should be prevented. As to the latter issue of who should be protected from
harm, both sides seem to agree that existing persons, or those likely to come
into existence, are the ones who should be protected from harm. The
existing person category includes persons with disabilities, prospective
parents, and the “healthy” embryos selected for implantation.149
145. Id.
146. Id.
147. Id.
148. Malek, supra note 143; see also, Harris, supra note 79, at 21 (discussing what Dr.
Malek terms “the Strong Claim”).
149. This categorization assumes that adherents to the disability rights critique and the
Strong Claim do not subscribe to the view that all preimplantation embryos are existing
persons, and thus must be implanted in order to avoid harm to the embryos themselves. This
view, advocated by the Catholic Church, represents an absolutist view of PGD that shuns all
use of the technique. See supra notes 72-78 and accompanying text. I do not read the
disability rights critique to say that PGD should never be used because it may lead to embryo
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There appears nothing mutually exclusive about preventing harm to all
three groups within the category of existing persons. Even if one favors
greater protection for one group, the other groups need not be made
vulnerable to harm as in a zero-sum game. The key to achieving equipoise
in group harm prevention is in agreeing which harms are worth preventing.
This determination is where the two perspectives are most likely to diverge.
Whereas the Strong Claim may advocate for PGD to select against embryos
that are certain or likely to experience mobility or sensory disabilities such as
paraplegia, blindness, or deafness, the disability rights critique may argue
these conditions do not pose harm to the individual and therefore selecting
against them is a form of discrimination against existing persons with the
deficits. Even if the disability community agreed that it is better for a child to
be born fully ambulatory with all senses intact, it would continue to worry
about the slippery slope upon which PGD is sure to fall. Selecting against
severe mobility and sensory deficits could easily morph into deselecting
embryos with extremely mild forms of the disability, such as those destined to
be pigeon toed, color blind, or tone deaf, should these conditions ever be
traced to a genetic cause.
Will the ability to prevent harm to offspring that is both grave and trivial
translate into the use of PGD to discard all but the Renaissance embryos of
the twenty-first century? I think the answer is no. First, from an efficiency
standpoint, it seems unlikely that IVF plus PGD will ever overtake the oldfashioned way of reproducing. The cost, time, and surgical invasion150
required make it an unlikely rival for natural conception. Still, the worry
remains that the small subset of parents who do invoke PGD will ratchet up
the indications for its use, widening the circle from individuals with a family
history of a devastating disease to those bent on eliminating even slight
imperfections in their family tree. If this wider clientele does emerge, will a
more routine use of PGD impact the way we view illness and health in our
society, as some critics have worried? Will our ability to select against mild
and manageable disease translate into intolerance of those with such
genetic disorders? Again, I am persuaded to answer in the negative.
The trajectory of modern medicine suggests that we will continue to
search out causes and cures for a broad range of maladies, but that such

discard. Nothing in its concern for the lives of individuals with disabilities suggests that it
insists on birthing infants whose life span would be a handful of years and who would suffer
great pain throughout. Instead, the critique reads as a plea for society to recognize the
beneficial and productive lives that persons with disabilities lead.
150. The surgical invasion refers to the surgery required to extract mature eggs from a
woman’s ovaries in order to form embryos using IVF. PGD can only be performed on
extracorporeal embryos, thus IVF is an essential first step to genetic testing of preimplantation
embryos. See COOK ET AL., supra note 3, at §9.7.
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discoveries will have little impact on how we view those afflicted with the
ailments. The use of vaccines to prevent harm from disease provides a nice
counterpart to the use of PGD to prevent harm from genetic anomaly.
While vaccines are administered postnatally, and PGD is used prenatally,
both aim to prevent the onset of health diminishing conditions. Though
PGD is still in its infancy, it appears to be traveling a path similar to that
paved by vaccine development, initially targeting severe, life-threatening
diseases then gradually addressing less severe conditions as more is learned
about the technology.
As noted previously, PGD was developed in the late 1980s to detect
mostly lethal single-gene disorders that displayed high penetrance in
affected families, such as Tay-Sachs disease and Huntington’s disease.151
Today, embryologists can use PGD to detect over one hundred genetic
conditions, some of which are nonfatal, such as familial high cholesterol,
and others which pose a mere susceptibility to adult-onset disease, such as
breast or colon cancer.152 This pattern repeats the development of
vaccines, which at first were used to prevent fatal communicable diseases,
but today are routinely administered to avoid generally mild symptoms of
common childhood infections.
The first successful vaccination was created by Edward Jenner in 1796
to combat smallpox, a contagious disease that had plagued humankind for
centuries.153 A vaccination for yellow fever followed in 1937, and the wellknown polio vaccine was introduced in a large scale trial in 1954.154 The
President of the March of Dimes, Basil O’Connor, said of the polio vaccine
at its introduction:
I have just figured out that during the coming summer, thirty or forty
thousand children will get polio. About fifteen thousand of them will be
paralyzed and more than a thousand will die. If we have the capacity to
prevent this, we have a social responsibility . . . we are supported by the

151. See supra notes 50-54 and accompanying text.
152. Johns Hopkins U., The Genetics & Pub. Pol’y Ctr., Issue Brief: Preimplantation
Genetic Diagnosis (Feb. 27, 2006), at http://www.dnapolicy.org/policy.issue.php?action=
detail&issuebrief_id=7 (last visited Feb. 3, 2009).
153. Smithsonian, Nat’l Museum Am. Hist., Whatever Happened to Polio?: Two Vaccines,
at http://americanhistory.si.edu/polio/virusvaccine/vacraces.htm (last visited Feb. 3, 2009)
[hereinafter Whatever Happened to Polio?]; see generally Stefan Riedel, Edward Jenner and
the History of Smallpox and Vaccination, 18 PROC. (BAYLOR UNIV. MED. CENT.) 21 passim
(2005), at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1200696 (last visited Feb. 3,
2009) (describing the history of smallpox and its role in the development of the field of
immunology).
154. Whatever Happened to Polio?, supra note 153.
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people and it is our duty to save lives no matter how many difficulties may
be involved.155

Perhaps Mr. O’Connor expressed the first iteration of the Strong Claim
by framing the polio vaccine in terms of duty, but would he have been as
strong an advocate for inoculating infants against a less deadly disease? If
we have the capacity to prevent disease through vaccination, do we have a
social responsibility (duty) to do so? American pediatricians seem to answer
in the affirmative, in the form of their recommendations to parents regarding
childhood vaccinations. Today the American Academy of Pediatrics
recommends that children be vaccinated against fifteen diseases, some of
which overwhelmingly produce only mild symptoms in their host.156 For
example, the vaccination for chicken pox was introduced in the U.S. in
1995, and is now widely used despite the medical fact that the disease is
generally mild and short-lived in the vast majority of those affected.157 But
its severity in a small number of infected individuals supports its use as a
public health matter.158
In terms of the expectation problem, we should query whether the
widespread, although not universal, use of childhood vaccines has changed
the way we view children and adults who manifest the targeted disease.
Epidemiologic data suggests that over ninety percent of children old enough
to receive vaccinations do receive the inoculations, leaving around ten
percent of the population voluntarily or inadvertently unvaccinated.159 As a
result of either vaccine ineffectiveness, or the exposure of unvaccinated

155. Id. (quoting Basil O’Connor, President of March of Dimes, 1954).
156. CTRS. FOR DISEASE CONTROL & PREVENTION, RECOMMENDED IMMUNIZATION SCHEDULE
FOR PERSONS AGED 0-6 YEARS—UNITED STATES: 2008, available at www.cdc.gov/vaccines/recs/
schedules/downloads/child/2008/08_0-6yrs_schedule_pr.pdf (last visited Feb. 3, 2009).
157. See generally CTRS. FOR DISEASE CONTROL & PREVENTION, CHICKEN POX VACCINE:
WHAT YOU NEED TO KNOW, available at www.cdc.gov/vaccines/pubs/vis/downloads/visvaricella.pdf (last visited Feb. 3, 2009) (“Chickenpox (also called varicella) is a common
childhood disease. It is usually mild, but it can be serious, especially in young infants and
adults. It causes a rash, itching, fever, and tiredness. It can lead to severe skin infection,
scars, pneumonia, brain damage, or death. The chickenpox virus can be spread from person
to person through the air, or by contact with fluid from chickenpox blisters. . . . Before the
vaccine, about 11,000 people were hospitalized for chickenpox each year in the United
States. Before the vaccine, about 100 people died each year as a result of chickenpox in the
United States.”).
158. Id.; see also U.S. Nat’l Libr. of Med., Medline Plus, Chickenpox, at www.nlm.nih.gov/
medlineplus/ency/article/001592.htm (last visited Feb. 3, 2009).
159. See Jennifer Steinhauer, Rising Public Health Risk Seen as More Parents Reject
Vaccines, N.Y. TIMES, Mar. 21, 2008, at A1 (explaining that most unvaccinated children in the
U.S. are parented by “vaccine skeptics[,]” parents who seek exemption from state child
vaccination laws out of a personal belief that vaccines are either dangerous or unnecessary).
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individuals to the particular viruses, outbreaks do periodically occur.160
Loosely applying the disability rights critique to these incidents of (largely)
preventable diseases, we would expect to see widespread discrimination
against individuals (or their parents) whose voluntary refusal to be
vaccinated caused their disease syndrome. That is, if an individual has the
opportunity to prevent disease, then declines such opportunity, that
individual should be derided once the disease manifests for failing to protect
herself and possibly her community from harm.
Instead of shunning “vaccines deviants,” society appears to have
accepted them and accommodated their difference. For example, several
pediatric practices advertise their willingness to work with vaccine-adverse
parents, permitting them to sign an “informed refusal” form declining
vaccinations on behalf of their children.161 Also, a number of states have
enacted broad exemptions to their vaccine mandates, allowing parents to
opt out of required inoculations so long as they agree to keep their children
out of school during known outbreaks.162 While the presence of
preventable—and communicable—disease is concerning for the
commonweal, it has not wrought isolation, denial of treatment, or
discrimination against those who choose to live outside the bounds of
accepted medical practice. Being different, even “imperfect” from a
disease-resistance perspective, has not produced widespread social harm to
affected populations.
The take away message from the vaccine experience may be that the
ability to prevent disease does not necessarily translate into discrimination
against those who manifest the disease. Shifting back to PGD, there is
reason to believe that this observation will hold true for disease prevention
in the form of embryo selection. Allowing parents to choose to birth a child
free of known genetic disorders—even those associated with mild
symptomology or asymptomatic carrier status—should have little or no
impact on the treatment of living or to-be-born individuals who express
those genetic anomalies. Alternatively, permitting parents to forgo PGD and
risk birthing a child with genetic anomalies, while frowned upon as a breach
160. Id. (describing recent outbreaks of measles, mumps and pertussis).
161. For example, Dr. Robert Sears, a pediatrician and author of THE VACCINE BOOK
(2007), describes himself as a “vaccine-friendly” practitioner, meaning he is willing to accept
patients in his practice that wish to delay or decline vaccinations for their children. His website
compiles and lists other “vaccine friendly” pediatricians. See AskDrSears.com, What is a
Vaccine-Friendly
Doctor?,
at
www.askdrsears.com/thevaccinebook/Vaccine_Friendly_
Doctors.asp (last visited Feb. 3, 2009).
162. Id. But see Calandrillo, supra note 115 (expressing concern over growing use of
vaccine exemptions and recommending greater scrutiny of exemption requests). See Ctrs. for
Disease Control & Prevention, Nat’l. Vaccine Program Office: Immunization Laws, at
www.dhhs.gov/nvpo/law.htm (last updated Feb. 3, 2009).
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of parental duty by the Strong Claim, should likewise have no impact on
society’s perception of that individual’s worth. Disease prevention
technologies should be celebrated as a collective benefit when they
succeed, but their failures should never rest on the shoulders of any affected
individual.
In sum, it is likely that PGD will continue to gain audience as its ability to
reveal the embryonic genome improves. At the same time, it seems equally
unlikely that PGD will be a routine part of reproduction, as its cost and risk
barriers make it unattractive to most of the world’s prospective parents. Still,
for the subset that wishes to screen and choose among their early embryos,
the expectation problem will present. The expectation that parents should
routinely use PGD will likely impact only those parents who are already
predisposed to accessing prenatal genetic technologies.
For these
reprotech-inclined parents, PGD is the latest entry on the ART continuum
that has been in development for over three decades. This group may
regard PGD as a “must have” because it expedites the delivery of genetic
information and eliminates the abortion dilemma that accompanies other
forms of prenatal genetic testing. But the idea of a universal expectation to
use PGD seems clinically unrealistic. Mother Nature is a far more
compelling, efficient, and successful alternative to technically-assisted
procreation.
As for the second part of the expectation problem—that once PGD is
used it will result in deselection of embryos for milder and more benign
conditions—this is likely to be the case. PGD, like other forms of disease
prevention, will begin by tackling life-threatening conditions and gradually
expand to address less serious, albeit life-affecting, syndromes. Will this
incremental expansion change the way we view disease or those with
disease in our society? I think not. We will continue to seek out cures and
treatments for diseases grave and trivial because those who aspire for
greater health in our society demand and deserve nothing less.
Instead of fostering discrimination against those with lesser health,
advances in the treatment and prevention of serious diseases may instead
yield, as a byproduct, therapies useful for treating less devastating illness. A
modern day example of such fortuity can be found in the research
surrounding smallpox. We recently learned that after centuries of work to
combat, and virtually rid the world of smallpox, a drug used for this deadly
disease may also be useful in treating a far less serious, though annoying,
health scourge—the common cold. In May 2008, scientists announced the
successful application of a smallpox drug to protect against adenovirus,
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a.k.a. the common cold, in animal studies.163 Such is a common trajectory
in medical research— with a destination in mind, researchers stay alert to
useful detours along the way.
IV. CONCLUSION
Genetic technologies have and will continue to change the way we think
about our own health and that of our children. The ability to select or
discard early embryos on the basis of genetic health empowers parents to
make earlier and more profound medical decisions on behalf of their
offspring, possibly disrupting long held views about an individual’s capacity
to control his or her own health. PGD, with its increased sensitivity to detect
milder and later-onset diseases, actively shifts decision-making about health
from the affected person to the controlling parent, while tempting users to
eliminate even slight imperfections in their offspring. While worries abound
that PGD will promote recklessness toward health in children spared of
familial diseases, and disdain for those who do manifest genetic anomalies,
nothing in our past treatment of sickness and health suggests such a future.
The path of our plodding journey to improve human health was recently
described by Harvard Professor of Psychology Steven Pinker in response to
concerns that advances in technology will rob us of our basic human
dignity. “The reality is that biomedical research[,]” Professor Pinker
observed, “is a Sisyphean struggle to eke small increments in health from a
staggeringly complex, entropy-beset human body. It is not, and probably
never will be, a runaway train.”164 While some may yearn for PGD to forge
full-steam ahead to reveal more and more about the early human genome,
thus enabling greater micromanagement of our genetic offspring, what we
really should expect are baby steps in this neophyte technology whose own
life cycle will surely long outlast each of our own.

163. See Smallpox Drug May Protect Against Common Cold, U.S. NEWS & WORLD REP.,
May 20, 2008, at http://health.usnews.com/articles/health/healthday/2008/05/20/smallpoxdrug-may-protect-against--common-cold.html (last visited Feb. 3, 2009).
164. Steven Pinker, The Stupidity of Dignity, NEW REPUBLIC, May 28, 2008, at 28, 31.
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